高血压和心房动:弥合机制,风险和治疗之间的差距
Ibrahim Antoun1,2, Georgia R Layton2,3, Ali Nizam1
1Department of Cardiology, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester LE3 9QP, UK.
Medicina (Kaunas, Lithuania)
|February 26, 2025
概括
高血压通过改变心脏结构显著增加了心房动 (AF) 的风险. 控制血压,特别是通过氨酸-血管酶-氨系统 (RAAS) 阻断剂,可以降低AF发生率并改善治疗结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 公共卫生 公共卫生
背景情况:
- 心房动 (AF) 是一种常见的心律失常,与中风,心力衰竭和死亡率有关.
- 高血压是AF的主要可修改风险因素,导致心房结构和电气变化.
- 这些变化包括扩张,纤维化和压力过载,增加AF易感性.
研究的目的:
- 审查共享的高血压和心房的机制,风险和治疗方法.
- 了解高血压如何影响AF的发展和管理.
- 确定有效的策略,以减轻高血压患者的AF.
主要方法:
- 关于高血压和心房动的文献搜索.
- 分析共享的病理生理路径.
- 审查当前和新兴的治疗策略.
主要成果:
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 参与心房重塑和炎症,促进AF.
- 失控的高血压会影响AF治疗,如抗失常药物和导管切除.
- 血压控制,特别是RAAS抑制,降低了新发和复发的AF风险,改善了节律控制的成功.
结论:
- 结合血压控制,AF查和生活方式改变的综合策略至关重要.
- 需要对细胞机制,炎症,遗传学以及高血压驱动的AF个性化治疗进行进一步的研究.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
Antihypertensive Drugs: Angiotensin II Receptor Blockers
568
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
452
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
452
Antihypertensive Drugs: Direct Renin Inhibitors
469
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
469
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K


